HIPI Team 9 engaged in an ambitious partnership with two french biotech companies on modeling the function of anti-IL-2 receptor therapeutic antibodies
Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease
NOVA awarded €2.4 million to leverage Jinkō®, its best-in-class clinical trial simulation platform, to conduct in silico studies for graft-versus-host disease
Research academic teams of the consortium – Institut de Recherche Saint Louis1 & Institut Mondor de Recherche Biomédicale 2 – to receive €0.95 million for their collaborative work with ElsaLys on in vitro and in vivo mechanisms of action of inolimomab
ElsaLys Biotech utilising in silico studies to accelerate the European approval of inolimomab in both adult and paediatric populations with this rare and life-threatening disease
Lyon, France – 19 January 2021: The Silikotac Program consortium, consisting of ElsaLys Biotech, Novadiscovery (“NOVA”) and two expert academic teams from Hôpital St Louis (Paris) and Hôpital Henri Mondor (Paris), has been awarded €3.35 million in non-dilutive funding by Bpifrance to support development of inolimomab in graft-versus-host disease (GvHD), the main complication that may occur after an allogeneic hematopoietic stem cell transplantation. The ambition of the Silikotac Program is to create the first French industrial and scientific immunotherapy chain group focused on GvHD…
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.